The DOI matches its Crossref record; 308 of the 308 references it cites were found in a registry or an index.
Considerations for the Design of Antibody-Based Therapeutics
Open accessAbstract
Antibody-based proteins have become an important class of biologic therapeutics, due in large part to the stability, specificity, and adaptability of the antibody framework. Indeed, antibodies not only have the inherent ability to bind both antigens and endogenous immune receptors but also have proven extremely amenable to protein engineering. Thus, several derivatives of the monoclonal antibody format, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, have demonstrated efficacy for treating human disease, particularly in the fields of immunology and oncology. Reviewed here are considerations for the design of antibody-based therapeutics, including immunological context, therapeutic mechanisms, and engineering strategies. First, characteristics of antibodies are introduced, with emphasis on structural domains, functionally important receptors, isotypic and allotypic differences, and modifications such as glycosylation. Then, aspects of therapeutic antibody design are discussed, including identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and design of antibody derivatives based on fragmentation, oligomerization, or conjugation to other functional moieties. Finally, strategies to enhance antibody function through protein engineering are reviewed while highlighting the impact of fundamental biophysical properties on protein developability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–308 of 308
Yokota, A., Yukawa, K., Yamamoto, A., Sugiyama, K., Suemura, M., Tashiro, Y., Kishimoto, T., & Kikutani, H. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.11.5030 · Cited by 119
Structure and dynamics of IgE–receptor interactions: Fcε RI and CD 23/Fcε RII
Sutton, B. J., & Davies, A. M. (2015) · Immunological Reviews · doi:10.1111/imr.12340 · Cited by 117
Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy
Kellner, C., Otte, A., Cappuzzello, E., Klausz, K., & Peipp, M. (2017) · Transfusion Medicine and Hemotherapy · doi:10.1159/000479980 · Cited by 117
TRIM21 and the Function of Antibodies inside Cells
Rhodes, D. A., & Isenberg, D. A. (2017) · Trends in Immunology · doi:10.1016/j.it.2017.07.005 · Cited by 115
Antibody conjugates with unnatural amino acids.
Hallam, T., Wold, E. D., Wahl, A., & Smider, V. V. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00082 · Cited by 112
pH-dependent Binding Engineering Reveals an FcRn Affinity Threshold That Governs IgG Recycling
Borrok, M. J., Wu, Y., Beyaz, N., Yu, X., Oganesyan, V., Dall’Acqua, W. F., & Tsui, P. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.603712 · Cited by 111
A Structurally Distinct Human Mycoplasma Protein that Generically Blocks Antigen-Antibody Union
Grover, R. K., Zhu, X., Nieusma, T., Jones, T. M., Boero, I., MacLeod, A. S., Mark, A., Niessen, S., Kim, H. J., Kong, L., et al. (2014) · Science · doi:10.1126/science.1246135 · Cited by 110
Yu, X., Chan, H. T. C., Orr, C. M., Dadas, O., Booth, S. G., Dahal, L. N., Penfold, C. A., O'Brien, L., Mockridge, C. I., French, R. R., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.02.009 · Cited by 110
Molecular aspects of immunoglobulin A1 degradation by oral streptococci
Reinholdt, J., Tomana, M., Mortensen, S. B., & Kilian, M. (1990) · Infection and Immunity · doi:10.1128/iai.58.5.1186-1194.1990 · Cited by 107
Townsend, C. L., Laffy, J., Wu, Y.-C. B., O’Hare, J. S., Martin, V., Kipling, D., Fraternali, F., & Dunn‐Walters, D. K. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00388 · Cited by 104
Parola, C., Neumeier, D., & Reddy, S. T. (2017) · Immunology · doi:10.1111/imm.12838 · Cited by 103
Igawa, T., Haraya, K., & Hattori, K. (2016) · Immunological Reviews · doi:10.1111/imr.12392 · Cited by 101
Grevys, A., Bern, M., Foss, S., Bratlie, D. B., Moen, A. R., Gunnarsen, K. S., Aase, A., Michaelsen, T. E., Sandlie, I., & Andersen, J. T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401218 · Cited by 99
Lavinder, J. J., Horton, A. P., Georgiou, G., & Ippolito, G. C. (2014) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2014.11.007 · Cited by 97
Monoclonal antibodies: technologies for early discovery and engineering
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2017.1357002 · Cited by 97
High-resolution structures of the IgM Fc domains reveal principles of its hexamer formation
Müller, R., Graewert, M. A., Kern, T., Madl, T., Peschek, J., Sattler, M., Groll, M., & Büchner, J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300547110 · Cited by 95
Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies
Smith, S. A., & Crowe, J. E. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.aid-0027-2014 · Cited by 95
Shatz-Binder, W., Chung, S., Li, B., Marshall, B., Tejada, M. L., Phung, W., Sandoval, W. N., Kelley, R. F., & Scheer, J. M. (2013) · mAbs · doi:10.4161/mabs.26307 · Cited by 94
Selecting and engineering monoclonal antibodies with drug-like specificity
Starr, C. G., & Tessier, P. M. (2019) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.01.008 · Cited by 94
Rasche, L., Duell, J., Castro, I. C., Dubljevic, V., Chatterjee, M., Knop, S. T., Hensel, F., Rosenwald, A., Einsele, H., Topp, M. S., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117945 · Cited by 93
Kraynov, E. A., Kamath, A. V., Walles, M., Tarcsa, E., Deslandes, A., Iyer, R. A., Datta‐Mannan, A., Sriraman, P., Bairlein, M., Yang, J. J., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.068049 · Cited by 93
Single B cell antibody technologies
Tiller, T. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.014 · Cited by 92
Jackman, J. K., Chen, Y., Huang, A. J. Y., Moffat, B., Scheer, J. M., Leong, S. R., Lee, W. P., Zhang, J., Sharma, N., Lu, Y., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.113910 · Cited by 91
Targeting FcRn for the modulation of antibody dynamics
Ward, E. S., Devanaboyina, S. C., & Ober, R. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.007 · Cited by 90
Kuhn, P., Fühner, V., Unkauf, T., Moreira, G. M. S. G., Frenzel, A., Miethe, S., & Hust, M. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201600002 · Cited by 90
C‐terminal lysine processing of human immunoglobulin G2 heavy chain in vivo
Cai, B., Pan, H., & Flynn, G. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.22933 · Cited by 89
Emerging Functions of Natural IgM and Its Fc Receptor FCMR in Immune Homeostasis
Wang, H., Coligan, J. E., & Morse, H. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00099 · Cited by 89
Mammalian cell display for the discovery and optimization of antibody therapeutics
Bowers, P. M., Horlick, R. A., Kehry, M. R., Neben, T. Y., Tomlinson, G. L., Altobell, L., Zhang, X., Macomber, J. L., Krapf, I. P., Wu, B. F., et al. (2013) · Methods · doi:10.1016/j.ymeth.2013.06.010 · Cited by 88
Magdelaine–Beuzelin, C., Vermeire, S., Goodall, M. D., Baert, F., Noman, M., Assche, G. V., Ohresser, M. C. P., Degenne, D., Dugoujon, J., Jefferis, R., et al. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32832a06bf · Cited by 88
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
Li, W., Zhu, Z., Chen, W., Feng, Y., & Dimitrov, D. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01554 · Cited by 87
Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Zhukovsky, E. A., Morse, R. J., & Maus, M. V. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.02.006 · Cited by 86
Immunoglobulin isotype knowledge and application to Fc engineering
Brezski, R. J., & Georgiou, G. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.002 · Cited by 86
Cell-Free Synthesis Meets Antibody Production: A Review
Stech, M., & Kubick, S. (2015) · Antibodies · doi:10.3390/antib4010012 · Cited by 83
Fc Sialylation Prolongs Serum Half-Life of Therapeutic Antibodies
Bas, M., Terrier, A., Jacque, E., Dehenne, A., Pochet-Béghin, V., Beghin, C., Dezetter, A.-S., Dupont, G., Engrand, A., Beaufils, B., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800896 · Cited by 82
Bumbaca Yadav, D., Sharma, V. K., Boswell, C. A., Hotzel, I., Tesar, D., Shang, Y., Ying, Y., Fischer, S. K., Grogan, J. L., Chiang, E. Y., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.692434 · Cited by 82
Bispecific antibodies for delivery into the brain
Watts, R. J., & Dennis, M. S. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.023 · Cited by 82
Ternant, D., Arnoult, C., Pugnière, M., Dhommée, C., Drocourt, D., Pérouzel, É., Passot, C., Baroukh, N., Mulleman, D., Tiraby, G., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1501780 · Cited by 82
Gorovits, B., Wakshull, E., Pillutla, R. C., Xu, Y., Manning, M. S., & Goyal, J. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.05.010 · Cited by 81
Hu, S., Fu, W., Xu, W., Yang, Y., Cruz, M., Berezov, S. D., Jorissen, D., Takeda, H., & Zhu, W. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1670 · Cited by 81
Demeule, B., Shire, S. J., & Liu, J. (2009) · Analytical Biochemistry · doi:10.1016/j.ab.2009.03.012 · Cited by 80
Kelton, W., Mehta, N., Charab, W., Lee, J., Lee, C., Kojima, T., Kang, T. H., & Georgiou, G. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.10.017 · Cited by 79
Mimoto, F., Igawa, T., Kuramochi, T., Katada, H., Kadono, S., Kamikawa, T., Shida-Kawazoe, M., & Hattori, K. (2013) · mAbs · doi:10.4161/mabs.23452 · Cited by 79
Bakhtiar, R. (2016) · Biotechnology Letters · doi:10.1007/s10529-016-2160-x · Cited by 78
Shim, H. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.10.063 · Cited by 77
Detection and Characterization of Subvisible Aggregates of Monoclonal IgG in Serum
Filipe, V., Poole, R. A., Oladunjoye, O., Braeckmans, K., & Jiskoot, W. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0749-x · Cited by 76
Harnessing Fc receptor biology in the design of therapeutic antibodies
Sondermann, P., & Szymkowski, D. E. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.03.005 · Cited by 76
Proteins behaving badly: emerging technologies in profiling biopharmaceutical aggregation
Hamrang, Z., Rattray, N. J. W., & Pluen, A. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.05.004 · Cited by 75
Borrok, M. J., Luheshi, N., Beyaz, N., Davies, G. C., Legg, J. W., Wu, H., Dall’Acqua, W. F., & Tsui, P. (2015) · mAbs · doi:10.1080/19420862.2015.1047570 · Cited by 73
Ortiz, D. F., Lansing, J. C., Rutitzky, L. I., Kurtagic, E., Prod’homme, T., Choudhury, A., Washburn, N., Bhatnagar, N., Beneduce, C., Holte, K., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9418 · Cited by 73
Ito, T., & Tsumoto, K. (2013) · Protein Science · doi:10.1002/pro.2340 · Cited by 72
Impact of Intrinsic Affinity on Functional Binding and Biological Activity of EGFR Antibodies
Zhou, Y., Goenaga, A.-L., Harms, B. D., Zou, H., Lou, J., Conrad, F., Adams, G. P., Schoeberl, B., Nielsen, U. B., & Marks, J. D. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1038 · Cited by 72
Völkel, T., Korn, T., Bach, M., Müller, R., & Kontermann, R. E. (2001) · Protein Engineering Design and Selection · doi:10.1093/protein/14.10.815 · Cited by 71
Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics
Ju, M., & Jung, S. T. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.013 · Cited by 71
Bartelds, G. M., de Groot, E. R., Nurmohamed, M. T., Hart, M. H. L., van Eede, P. H., Wijbrandts, C. A., Crusius, J. B. A., Dijkmans, B. A. C., Tak, P. P., Aarden, L. A., et al. (2010) · Arthritis Research & Therapy · doi:10.1186/ar3208 · Cited by 71
de Marco, A. (2015) · Microbial Cell Factories · doi:10.1186/s12934-015-0320-7 · Cited by 69
Germline VH/VL pairing in antibodies
Jayaram, N., Bhowmick, P., & Martin, A. C. R. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs043 · Cited by 69
Fab-based bispecific antibody formats with robust biophysical properties and biological activity
Wu, X., Sereno, A., Huang, F., Lewis, S. M., Lieu, R., Weldon, C. L., Torres, C., Fine, C., Batt, M. A., Fitchett, J. R., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1022694 · Cited by 68
A Perspective on the Structure and Receptor Binding Properties of Immunoglobulin G Fc
Hanson, Q., & Barb, A. W. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00299 · Cited by 68
van den Bremer, E. T. J., Beurskens, F. J. M., Voorhorst, M., Engelberts, P. J., de Jong, R. N., van der Boom, B. G., Cook, E. M., Lindorfer, M. A., Taylor, R. P., van Berkel, P. H. C., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1046665 · Cited by 66
White, A. L., Dou, L., Chan, H. T. C., Field, V. L., Mockridge, C. I., Moss, K., Williams, E. L., Booth, S. G., French, R. R., Potter, E. A., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303204 · Cited by 66
Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice
Newkirk, M. M., Novick, J., Stevenson, M. M., Fournier, M.-J., & Apostolakos, P. (1996) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.1996.d01-847.x · Cited by 66
Dimers and multimers of monoclonal IgG1 exhibit higher in vitro binding affinities to Fcγ receptors
Luo, Y., Lu, Z., Raso, S. W., Entrican, C., & Tangarone, B. S. (2009) · mAbs · doi:10.4161/mabs.1.5.9631 · Cited by 64
Shark IgNAR-derived binding domains as potential diagnostic and therapeutic agents
Matz, H. C., & Dooley, H. M. (2018) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2018.09.007 · Cited by 62
Pardridge, W. M. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1230195 · Cited by 61
Hong, E., Erickson, H. K., Lutz, R. J., Whiteman, K. R., Jones, G. E., Kovtun, Y., Blanc, V., & Lambert, J. M. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00175 · Cited by 59
Leusen, J. H. W. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.09.005 · Cited by 59
Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies
Leipold, D. D., & Prabhu, S. (2018) · Clinical and Translational Science · doi:10.1111/cts.12597 · Cited by 59
IgE immunotherapy: A novel concept with promise for the treatment of cancer
Josephs, D. H., Spicer, J. F., Karagiannis, P., Gould, H. J., & Karagiannis, S. N. (2014) · mAbs · doi:10.4161/mabs.27029 · Cited by 58
Durben, M., Schmiedel, D., Hofmann, M., Vogt, F., Nuebling, T., Pyż, E., Bühring, H., Rammensee, H., Salih, H. R., Große‐Hovest, L., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.2 · Cited by 56
Antibody-drug conjugates for non-oncological indications
Liu, R., Wang, R. E., & Wang, F. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1161753 · Cited by 56
The birth pangs of monoclonal antibody therapeutics: The failure and legacy of Centoxin
Marks, L. V. (2012) · mAbs · doi:10.4161/mabs.19909 · Cited by 55
Modulating antibody pharmacokinetics using hydrophilic polymers
Chen, C., Constantinou, A., & Deonarain, M. P. (2011) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2011.602399 · Cited by 54
General Overview of Radioimmunotherapy of Solid Tumors
Navarro‐Teulon, I., Lozza, C., Pèlegrin, A., Vivès, É., & Pouget, J. (2013) · Immunotherapy · doi:10.2217/imt.13.34 · Cited by 54
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Herrington-Symes, A. P., Farys, M., Khalili, H., & Brocchini, S. (2013) · Advances in Bioscience and Biotechnology · doi:10.4236/abb.2013.45090 · Cited by 53
Optimizing antibody expression: The nuts and bolts
Ayyar, B. V., Arora, S., & Ravi, S. S. (2017) · Methods · doi:10.1016/j.ymeth.2017.01.009 · Cited by 53
Therapeutic application of antibody fragments in autoimmune diseases: current state and prospects
Fernandes, J. C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.06.003 · Cited by 53
Huh, J. H., White, A. J., Brych, S. R., Franey, H., & Matsumura, M. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23505 · Cited by 52
Glycans of Antibodies as a Specific Site for Drug Conjugation Using Glycosyltransferases
Qasba, P. K. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00173 · Cited by 52
Lohse, S., Brunke, C., Derer, S., Peipp, M., Boross, P., Kellner, C., Beyer, T., Dechant, M., van de Winkel, J. G. J., Leusen, J. H. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.353060 · Cited by 51
Relevance of radiobiological concepts in radionuclide therapy of cancer
Kumar, C., Shetake, N. G., Desai, S., Kumar, A., Samuel, G., & Pandey, B. N. (2016) · International Journal of Radiation Biology · doi:10.3109/09553002.2016.1144944 · Cited by 49
Svilenov, H. L., Markoja, U., & Winter, G. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.01.004 · Cited by 49
IgM-Dependent Phagocytosis in Microglia Is Mediated by Complement Receptor 3, Not Fcα/μ Receptor
Weinstein, J. R., Quan, Y., Hanson, J. F., Colonna, L., Iorga, M., Honda, S.-I., Shibuya, K., Shibuya, A., Elkon, K. B., & Möller, T. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401195 · Cited by 47
Karagiannis, S. N., Josephs, D. H., Bax, H. J., & Spicer, J. F. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0428 · Cited by 45
Engineered Protease-resistant Antibodies with Selectable Cell-killing Functions
Kinder, M., Greenplate, A. R., Grugan, K. D., Soring, K. L., Heeringa, K., McCarthy, S. G., Bannish, G., Perpetua, M., Lynch, F., Jordan, R. E., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.486142 · Cited by 44
IgG-Fc N-glycosylation at Asn297 and IgA O-glycosylation in the hinge region in health and disease
Xue, J., Zhu, L.-P., & Wei, Q. (2013) · Glycoconjugate Journal · doi:10.1007/s10719-013-9481-y · Cited by 43
Antibody conjugation via one and two C-terminal selenocysteines
Li, X., Yang, J., & Rader, C. M. (2013) · Methods · doi:10.1016/j.ymeth.2013.05.023 · Cited by 43
Castoldi, R., Jucknischke, U., Pradel, L. P., Arnold, E., Klein, C., Scheiblich, S., Niederfellner, G. J., & Sustmann, C. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs048 · Cited by 43
Tam, S. H., McCarthy, S. G., Armstrong, A., Somani, S., Wu, S., Liu, X., Gervais, A., Ernst, R., Saro, D., Decker, R., et al. (2017) · Antibodies · doi:10.3390/antib6030012 · Cited by 43
Aggregation of biopharmaceuticals in human plasma and human serum
Arvinte, T., Palais, C., Green-Trexler, E., Gregory, S., Mach, H., Narasimhan, C. N., & Shameem, M. (2013) · mAbs · doi:10.4161/mabs.24245 · Cited by 42
Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization
Foss, S., Grevys, A., Sand, K. M. K., Bern, M., Blundell, P. A., Michaelsen, T. E., Pleass, R. J., Sandlie, I., & Andersen, J. T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.033 · Cited by 39
High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1
Opaliński, Ł., Szymczyk, J., Sochacka, M., Kucińska, M. K., Krowarsch, D., Zakrzewska, M., & Otlewski, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051435 · Cited by 35
Disulfide linkage engineering for improving biophysical properties of human VH domains
Kim, D. Y., Kandalaft, H., Ding, W., Ryan, S., van Faassen, H., Hirama, T., Foote, S. J., MacKenzie, R., & Tanha, J. (2012) · Protein Engineering Design and Selection · doi:10.1093/protein/gzs055 · Cited by 33
Eisen, A., Greenberg, B., Bowen, J., Arnold, D., & Caggiano, A. (2017) · Multiple Sclerosis Journal - Experimental, Translational and Clinical · doi:10.1177/2055217317743097 · Cited by 33
Krayukhina, E., Noda, M., Ishii, K., Maruno, T., Wakabayashi, H., Tada, M., Suzuki, T., Ishii‐Watabe, A., Katô, M., & Uchiyama, S. (2017) · mAbs · doi:10.1080/19420862.2017.1297909 · Cited by 32
Rapid Purification of Human Bispecific Antibodies via Selective Modulation of Protein A Binding
Zwolak, A., Leettola, C. N., Tam, S. H., Goulet, D. R., Derebe, M. G., Pardinas, J. R., Zheng, S., Decker, R., Emmell, E., & Chiu, M. L. (2017) · Scientific Reports · doi:10.1038/s41598-017-15748-0 · Cited by 32
Self-citationEngineered Autonomous Human Variable Domains
Nilvebrant, J., Tessier, P. M., & Sidhu, S. S. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160921143011 · Cited by 30
Tradtrantip, L., Felix, C. M., Spirig, R., Morelli, A. B., & Verkman, A. S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.002 · Cited by 30
Luo, S., & Zhang, B. (2015) · mAbs · doi:10.1080/19420862.2015.1087636 · Cited by 29
Nagashima, H., Tezuka, T., Tsuchida, W., Maeda, H., Kohroki, J., & Masuho, Y. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.02.003 · Cited by 27
Effect of Glycosylation on Cis/Trans Isomerization of Prolines in IgA1-Hinge Peptide
Narimatsu, Y., Kubota, T., Furukawa, S., Morii, H., Narimatsu, H., & Yamasaki, K. (2010) · Journal of the American Chemical Society · doi:10.1021/ja9106429 · Cited by 25
Shibuya, A., & Honda, S. (2015) · Immunological Reviews · doi:10.1111/imr.12345 · Cited by 24
Liu, B. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2748-7 · Cited by 24
Enhancement of antibody functions through Fc multiplications
Wang, Q., Chen, Y., Pelletier, M. R., Cvitkovic, R., Bonnell, J. C., Chang, C.-Y., Koksal, A. C., O'Connor, E., Gao, X., Yu, X., et al. (2017) · mAbs · doi:10.1080/19420862.2017.1281505 · Cited by 21
Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics
Bajardi-Taccioli, A., Blum, A., Xu, C., Sosic, Z., Bergelson, S., & Feschenko, M. S. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.06.031 · Cited by 16
A pro-inflammatory role of Fcα/μR on marginal zone B cells in sepsis
Shibuya, A., Honda, S.-I., & Shibuya, K. (2017) · International Immunology · doi:10.1093/intimm/dxx059 · Cited by 16
High-Throughput Assay for Measuring Monoclonal Antibody Self-Association and Aggregation in Serum
Li, X., Geng, S. B., Chiu, M. L., Saro, D., & Tessier, P. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00010 · Cited by 10
Next-Generation Techniques for Discovering Human Monoclonal Antibodies
Лушова, А. А., Byazrova, M. G., Prilipov, A. G., Садыкова, Г. К., Kopylov, A. T., & Filatov, A. V. (2017) · Molecular Biology · doi:10.1134/s0026893317060103 · Cited by 8
Jain, A. K., Poonia, B., So, E. C., Vyzasatya, R., Burch, E. E., Olsen, H. S., Mérigeon, E. Y., Block, D. S., Zhang, X., Schulze, D. H., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.009 · Cited by 7
Cited by
Avidity in antibody effector functions and biotherapeutic drug design
Oostindie, S. C., Lazar, G. A., Schuurman, J., & Parren, P. W. H. I. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00501-8 · Cited by 298
Antibodies Targeting the Transferrin Receptor 1 (TfR1) as Direct Anti-cancer Agents
Candelaria, P. V., Leoh, L. S., Penichet, M. L., & Daniels-Wells, T. R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.607692 · Cited by 268
Predicting antibody developability profiles through early stage discovery screening
Bailly, M., Mieczkowski, C., Juan, V., Metwally, E., Tomazela, D., Baker, J., Uchida, M., Kofman, E., Raoufi, F., Motlagh, S., et al. (2020) · mAbs · doi:10.1080/19420862.2020.1743053 · Cited by 228
The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics
Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J.-Y., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 155
Huang, Y., Del Nagro, C. J., Balic, K., Mylott, W. R., Ismaiel, O. A., Ma, E., Faria, M., Wheeler, A. M., Yuan, M., Waldron, M. P., et al. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c01187 · Cited by 29
Metadata
- Authors
- Goulet, D. R., & Atkins, W. M.
- Venue
- Journal of Pharmaceutical Sciences
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 109
- Issue
- 1
- Pages
- 74-103
- ISSN
- 0022-3549 (ISSN-L)
- OpenAlex
- W2948074633
- Cited by
- 302
- References
- 308
- FWCI
- 15.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.